Argos Therapeutics, Inc. (NASDAQ:ARGS) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
Item 5.02   Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers

(b)         On March 31, 2017, Ralph Snyderman, M.D. voluntarily resigned from Argos Therapeutics, Inc.’s (the "Company") Board of Directors (“the Board”), effective as of that date. There were no disagreements between Dr. Snyderman and the Company or any officer or director of the Company which led to Dr. Snyderman’s resignation. Dr. Snyderman had served on the Board since December 2016. With the resignation, Dr. Snyderman also resigned as a member of the Company’s Audit Committee.

About Argos Therapeutics, Inc. (NASDAQ:ARGS)

Argos Therapeutics, Inc. (Argos) is an immuno-oncology company. The Company is focused on the development and commercialization of individualized immunotherapies for the treatment of cancer and infectious diseases based on its technology platform called Arcelis. The Company’s Arcelis technology platform utilizes biological components from a patient’s own cancer cells or virus to generate individualized immunotherapies. The Company is engaged in the development of AGS-003 for the treatment of metastatic renal cell carcinoma (mRCC), and other cancers. It is conducting a pivotal Phase III clinical trial of AGS-003 plus sunitinib or another targeted therapy for the treatment of newly diagnosed mRCC under a special protocol assessment (SPA). It is engaged in the development of AGS-004 for the treatment of Human Immunodeficiency Virus (HIV). It has conducted over three clinical trials of AGS-004, including a Phase IIb clinical trial, Phase IIa clinical trial and Phase I clinical trial.

Argos Therapeutics, Inc. (NASDAQ:ARGS) Recent Trading Information

Argos Therapeutics, Inc. (NASDAQ:ARGS) closed its last trading session down -0.087 at 0.470 with 5,510,300 shares trading hands.